StemCells, Inc.
American biopharmaceutical company
 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1 January 1992  |
| Headquarters | Newark , United States |
Key people | Ian Massey (CEO) Irving L. Weissman, M.D. (Founder) |
| Website | www.stemcellsinc.com |
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.[1][2]
They are being studied in early stage trials.[3][4]
In March 2020, Microbot Medical Inc. announced the appointment of Eyal Morag, M.D. to Chief Medical Officer.[5]
References
- ^ Falco, Miriam. (Sept. 7, 2012). "A tiny step forward for spinal cord injuries."
- ^ Le Roux, Mariette. (March 5, 2014). "Science sees future beyond Paralympics."
- ^ http://www.clinicaltrials.gov/ct2/show/NCT02163876
- ^ "StemCells Inc says spinal injury therapy shows promise". Reuters. 2015-11-18. Retrieved 2015-12-23.
- ^ "Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer". BioSpace. Retrieved 2020-03-03.
External links
- StemCells, Inc. website
| Authority control databases |
|
|---|
